1. In Vivo
  2. >>Business Strategy

Lead From The Front – But Resist Micromanaging

An Interview With Rising Leader Greg Mullen, CEO of Theragnostics

 
• By Sten Stovall

Theragnostics’ CEO Greg Mullen aims to use his wide-ranging “hands-on” scientific and commercial experience to help clinch a $45m series A financing round that will fund a Phase I/II basket study to develop the biotech’s lead radiotherapeutic PARP inhibitor.

Paper boat
• Source: Shutterstock

Shepherding radiopharmaceuticals start-up Theragnostics Ltd. up to and through a planned series A financing this year is a key strategic aim of its CEO Greg Mullen. The funding round will give the transatlantic biotech the financial runway to put its lead therapeutic product, an iodine-123 labeled PARP inhibitor, into clinical development as a targeted radionuclide therapy.

Called THG-009, the radiotherapeutic poly (ADP-ribose) polymerase inhibitor is designed to deliver doses of radiation to tumours, killing cancer cells...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

Mapping Biopharma’s AI Strategy: From Custom Datasets to Foundation Models

 
• By David Wild

Biotech companies are pursuing diverse AI strategies beyond expensive custom data generation: foundation model fine-tuning, data-efficient computational methods and targeted proprietary datasets. In Vivo takes a look at some examples.

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

More from In Vivo